Stockscreener 앱 받기
5.73
0.35%
0.02
시장 영업 전:
5.74
0.010
+0.17%
전일 마감가:
$5.71
열려 있는:
$5.69
하루 거래량:
5.71M
Relative Volume:
0.86
시가총액:
$2.01B
수익:
$143.05M
순이익/손실:
$-145.99M
주가수익비율:
-13.38
EPS:
-0.4282
순현금흐름:
$-134.06M
1주 성능:
-5.60%
1개월 성능:
-15.24%
6개월 성능:
+33.88%
1년 성능:
+76.85%
1일 변동 폭
$5.535
$5.78
1주일 범위
$5.535
$6.26
52주 변동 폭
$2.99
$9.75
Nuvation Bio Inc Stock (NUVB) Company Profile
명칭
Nuvation Bio Inc
전화
332-208-6102
주소
1500 BROADWAY, NEW YORK
Compare NUVB vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
5.73 | 2.01B | 143.05M | -145.99M | -134.06M | -0.4282 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-11-19 | 개시 | B. Riley Securities | Buy |
| 2025-09-30 | 개시 | Jefferies | Buy |
| 2025-04-23 | 개시 | Citizens JMP | Mkt Outperform |
| 2024-03-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-03-26 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2023-01-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-08-02 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-08-02 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2022-05-04 | 개시 | H.C. Wainwright | Buy |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-04-06 | 개시 | RBC Capital Mkts | Outperform |
| 2021-03-08 | 개시 | BMO Capital Markets | Outperform |
| 2021-03-08 | 개시 | BTIG Research | Buy |
| 2021-03-08 | 개시 | Cowen | Outperform |
| 2021-03-08 | 개시 | Jefferies | Buy |
| 2021-03-08 | 개시 | Wedbush | Outperform |
모두보기
Nuvation Bio Inc 주식(NUVB)의 최신 뉴스
NUVB Stock Is Soaring Today — Why RBC Sees $3B Opportunity In Nuvation Bio's Brain Cancer Drug - Stocktwits
September 2026's High Insider Ownership Growth Leaders - simplywall.st
What Nuvation Bio (NUVB)'s Updated Cancer Drug Label Means For Shareholders - simplywall.st
Nuvation Bio Inc. (NUVB): Investor Outlook With A 115.82% Potential Upside - DirectorsTalk Interviews
Nuvation Bio stock gains on FDA label update for IBTROZI By Investing.com - Investing.com Australia
Why Is Nuvation Bio Stock Gaining Thursday? - Benzinga
Nuvation Bio stock gains on FDA label update for IBTROZI - Investing.com
Nuvation Bio Inc. (NUVB) latest stock news and headlines – Yahoo Finance - Yahoo Finance Singapore
Nuvation Bio stock rises on Ibtrozi label update (NUVB:NYSE) - Seeking Alpha
Nuvation Bio Inc. (NYSE:NUVB) Wins FDA OK To Add ~50-Month DOR To IBTROZI Label - TradingView
A cancer drug showed responses lasting nearly four years. FDA approved Nuvation Bio's label update. - Stock Titan
Nuvation Bio (NUVB) Reports Consistent IBTROZI Results Across ROS1 Positive NSCLC Subgroups - simplywall.st
Nuvation Bio (NUVB) Reports IBTROZI Efficacy Across ROS1 Lung Cancer Subgroups - finance.yahoo.com
Citizens maintains Nuvation Bio stock rating on competitive edge - Investing.com
Nuvation Bio presents subgroup analyses for lung cancer drug By Investing.com - Investing.com South Africa
J.P. Morgan Maintains Nuvation Bio(NUVB.US) With Buy Rating - Moomoo
Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer - Investing News Network
Nuvation Bio presents subgroup analyses for lung cancer drug - Investing.com
Nuvation Bio Inc. (NYSE:NUVB) Reports Consistent IBTROZI Efficacy Across ROS1+ NSCLC Subgroups - TradingView
Nearly 9 in 10 patients responded to a lung cancer drug after chemotherapy. - Stock Titan
Nuvation Bio (NUVB) Stock Looks Stretched Despite Its 354% Three Year Run - webull.com
NUVB: IBTROZI dominates ROS1 with best-in-class efficacy, while safusidenib advances across glioma subtypes - TradingView
Nuvation Bio at 12th Annual Cantor Fitzgerald Global Healthcare Conference: pipeline gains - Investing.com
NUVB: IBTROZI’s superior efficacy and safety drive rapid market share gains, with a strong pipeline advancing - TradingView
Nuvation Bio at citigroup biopharma summit: growth rests on three pillars - Investing.com Canada
NUVB: IBTROZI and safusidenib drive growth with best-in-class efficacy and expanding global opportunities - TradingView
NUVB: IBTROZI and safusidenib drive strong growth, with major clinical and commercial milestones ahead - TradingView
Nuvation Bio (NUVB) Slips to $6.52 as Traders Weigh Support and Resistance LevelsDefined Outcome ETF - careplusvn.com
Jim Cramer sends strong 5-word message on surging biotech stock - Yahoo Finance
Jim Cramer: This Health Care Stock Is Pure Spec, The Only Neocloud I Like Is... - Benzinga
Cramer's lightning round: Nuvation Bio 'is a pure spec' - CNBC
Does Nuvation Bio (NUVB) Have the Potential to Rally 91.92% as Wall Street Analysts Expect? - Yahoo Finance
Nuvation Bio to Participate in Upcoming Investor Conferences - Investing News Network
Nuvation Bio (NUVB) Upgraded to Buy: Here's Why - Yahoo Finance
Nuvation: Why I'm Downgrading To Hold Despite Progress On NSCLC And Glioma Fronts (NUVB) - Seeking Alpha
NUVB|Nuvation Bio Inc|Price:7.100|Chg%:+0.340 - TradingKey
Nuvation Bio | 4: Statement of changes in beneficial ownership of securities-Officer Hattersley Gary - Moomoo
Nuvation Bio (NUVB) CSO sells 100K shares at $7.09 - Stock Titan
Nuvation Bio stock rises after Cantor starts at Overweight - Investing.com
Why is Nuvation Bio stock rallying today? By Investing.com - Investing.com Canada
Nuvation Bio rises as Cantor initiates at overweight - Seeking Alpha
Cantor Fitzgerald initiates Nuvation Bio stock with overweight rating - Investing.com
Cantor Fitzgerald initiates Nuvation Bio stock with overweight rating By Investing.com - Investing.com India
Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma - Investing News Network
JPMorgan sees 100% upside in overlooked cancer drug stock - thestreet.com
FDA grants Nuvation fast-track status for safusidenib in IDH1-mutant glioma - AllSci
Nuvation Bio receives FDA fast track status for brain cancer drug - Investing.com South Africa
Market Sentiment Around Loss-Making Nuvation Bio Inc. (NYSE:NUVB) - Moomoo
One NYSEListed Biotechnology Stock at Resistance Level – NUVB - kalkine.ca
Nuvation (NUVB) Results Breakdown: EPS Comes in Above Forecast for the Current Session; Share Response - Vinanet
Nuvation Bio Inc (NUVB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Nuvation Bio Inc (NUVB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.11%
1.87%
자본화:
|
볼륨(24시간):